BD to Spend $1.2 Billion Upgrading Manufacturing Capacity for Prefillable Syringes

By Dave Sebastian

Becton, Dickinson & Co. said Wednesday it plans to spend about $1.2 billion expanding its manufacturing capacity for prefillable syringes and advanced drug delivery systems over the next four years.

The company said it will upgrade the capacity at six global locations and add a new Europe manufacturing facility, which it expects to start operating by the end of 2023.

"This investment positions BD to have the needed surge capacity for increased prefillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines," said Eric Borin, worldwide president of BD Pharmaceutical Systems.

Six manufacturing facilities will get a portion of the investment include those in Columbus, Neb.; Cuautitlan, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, U.K.; and Tatabanya, Hungary.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

December 02, 2020 07:29 ET (12:29 GMT)

Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2024 to Apr 2024